Key Summary Points {#FPar1}
==================

**Why carry out this study?**Use of azathioprine has been limited by the possibility of severe leukopenia which can be partially prevented by genetic screening. Mutation of nucleoside diphosphate-linked moiety X motif 15 (*NUDT15*) and thiopurine methyltransferase (*TPMT*) had been shown to be predictive in azathioprine-induced neutropenia mainly in inflammatory bowel disease and leukemia among some populationsTo determine the contribution of*NUDT15* (and*TPMT*) mutations to the development of toxicity induced by azathioprine treatment, especially neutropenia, in Han Chinese patients with dermatologic diseases**What was learned from the study?**All three patients carrying homozygous variant (T/T) developed neutropenia and the age-, sex-, and dose-adjusted risk of carrying heterozygous variant (C/T) compared to wild type is 9.383 (95% CI 1.32--66.96)However, about one quarter of the patients with azathioprine-induced neutropenia in our study carried no mutation of*NUDT15* or*TPMT*Pretreatment screening of*NUDT15* might reduce the chance of azathioprine-induced neutropenia in Han Chinese patients with dermatologic diseases

Introduction {#Sec1}
============

Azathioprine is a synthetic purine analogue derived from 6-mercaptopurine which has been used for the treatment of various inflammatory and neoplastic diseases for decades. Azathioprine is extensively metabolized, and only about 2% is excreted unchanged in the urine \[[@CR1]\].

Azathioprine is generally well tolerated, but dose-limiting toxicity can lead to serious adverse drug reaction and cessation of the therapy in 9--28% of patients \[[@CR2]\]. Leukopenia is estimated to affect 1% of Caucasians and up to 7% of Asians \[[@CR3]\]. In recent years, pharmacogenetic studies revealed genetic susceptibility loci for thiopurine-induced early leukopenia which are different between ethnicities \[[@CR4]--[@CR6]\]. Thiopurine methyltransferase (*TPMT*) and inosine triphosphate pyrophosphohydrolase (*ITPA*) gene mutations account for the major genetic polymorphism markers for azathioprine adverse risk factors in Caucasians \[[@CR7], [@CR8]\]. In Asian patients, a variant with a c.415 C-to-T transition (rs116855232) in the nucleoside diphosphate-linked moiety X motif 15 (*NUDT15*) was strongly associated with thiopurine-induced early leukopenia \[[@CR9]--[@CR18]\]. NUDT15 catalyzes the conversion of cytotoxic thioguanine triphosphate to the non-toxic thioguanine monophosphate. The role of rs116855232 was first identified in Korean subjects with Crohn's disease treated with thiopurines in 2014 \[[@CR9]\]. Subsequently, more studies from Asian countries and Hispanics confirmed the role of*NUDT15* in azathioprine-induced leukopenia, not only in inflammatory bowel disease but also in autoimmune diseases, neurological diseases, and leukemia \[[@CR9]--[@CR18]\].

However, reports of*NUDT15* mutation in azathioprine-induced leukopenia are mainly in patients with inflammatory bowel diseases and acute lymphoblastic leukemia. Because difference in ethnicities and diseases may affect the sensitivity and specificity of the results, we would like to report our result of*NUDT15* p.R139C variant testing in Han Chinese patients with dermatology diseases.

The aim of our study was to determine the relative contribution of*NUDT15* mutations to the development of azathioprine-induced neutropenia, in Han Chinese patients with dermatologic diseases.

Methods {#Sec2}
=======

The study enrolled all consecutive patients older than 13 years old with dermatological diseases currently treated orally with azathioprine in our clinic. Samples were also collected from patients with documented leukopenia in our prior study after informed reconsent \[[@CR7]\]. The patients must have received azathioprine orally for at least 8 weeks or until adverse events. Complete blood count, differential count, and hepatic and renal function were checked regularly. The sex, age, types of dermatological diseases, azathioprine doses, the date and the number of lowest neutrophil count, and other side effects were recorded.

Azathioprine-induced neutropenia was defined as neutrophil count less than the lower normal limit without other identifiable causes of neutropenia. The severity was graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 \[[@CR19]\]. Grade 1, 2, 3, and 4 neutropenia was defined as neutrophil count less than lower limit but above 1500/mm^3^, 1000--1500/mm^3^, 500--1000/mm^3^, and less than 500/mm^3^, respectively. Early neutropenia was defined as neutropenia that developed within 8 weeks after the initiation of azathioprine higher than 1 mg/kg/day. Patients with leukopenia already before receiving azathioprine were excluded.

The DNA samples were obtained with a cotton tip application from the buccal mucosa or by blood sampling.*NUDT15* gene variant p.Arg139Cys (c.415C\>T, rs116855232) and*TPMT* gene variant p.Tyr240Cys (c.719A\>G, rs1142345) were detected using pyrosequencing and results were validated against Sanger sequencing. Pyrosequencing and Sanger sequencing primers were performed by BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher \#4337457) and determined by 3730XL DNA Analyzer (Applied Biosystems 3730XL) followed by AB DNA Sequencing Analysis Software v5.2.

Fisher's exact test, Wilcoxon rank sum test, and ANOVA test were used for standard comparisons of data. A *P* value less than 0.05 was defined as significant.

The study was approved by National Taiwan University Hospital Institutional Review Board (201805135RINB) and was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed consent to participant in the study was obtained from all patients; for any patients under the age of 18 informed consent from a parent/guardian was obtained.

Results {#Sec3}
=======

In total, we enrolled 56 patients (39 male, 17 female). The average age was 45.63 years old. The average age of female patients was 47.71 years old, which is slightly older than the average age of male patients (44.71 years old). The most common underlying disease was generalized eczema (*N* = 29), followed by atopic dermatitis (*N* = 22) (Table [1](#Tab1){ref-type="table"}). Four patients had two dermatologic diseases. Two patients had generalized eczema and systemic lupus erythematosus, and two patients had generalized eczema and psoriasis. The distribution of the disease among two genders did not reach statistical significance. The average body weight is significantly higher in male patients (69.11 kg) compared to female patients (55.14 kg, *P* = 0.0003). The average azathioprine dose is higher in female patients (1.62 mg/kg/day) than male patients (1.41 mg/kg/day, *P* = 0.0489) (Table [1](#Tab1){ref-type="table"}).Table 1Clinical and genetic characteristics of the patients and controlsTotalMaleFemale*P* valueCaseControl*P* valuePatient numbers5639171541Age (years) ± SD45.63 ± 21.2144.71 ± 21.9147.41 ± 19.990.5008^a^53.73 ± 22.0742.66 ± 20.340.0708^a^Sex (male to female)39:17NANA8:731:10Underlying diseases\*0.2536^b^0.0586^b^ Generalized eczema2919101118 Atopic dermatitis22175319 Psoriasis33003 Bullous pemphigoid20211 Pemphigus foliaceus11001 Dermatomyositis11001 SLE21120*NUDT15*0.4316^b^0.0003^b^ C/C362610432 C/T1710789 T/T33030Neutrophil count2688.15 ± 1632.762824.72 ± 1499.472382.85 ± 1911.730.2914^a^683.83 ± 424.643439.76 ± 1225.57\< 0.0001^a^Body weight (kg)64.86 ± 11.8769.11 ± 10.5255.14 ± 8.770.0003^a^61.29 ± 10.1666.18 ± 12.290.1734^a^Azathioprine dose (mg/kg/day)1.48 ± 0.351.41 ± 0.331.62 ± 0.350.0489^a^1.68 ± 0.381.40 ± 0.310.0273^a^*SD* standard variation, *NA* not applicable, *SLE* systemic lupus erythematosus\*Four patients had two dermatologic underlying diseases^a^Wilcoxon rank sum test^b^Fisher's exact test

The*NUDT15* genotypes are mostly C/C (*N* = 36, 64.29%). Heterozygous variant (C/T) accounts for 30.36% (*N* = 17) and homozygous variant (T/T) accounts for 5.36% (*N* = 3). Among these patients, 15 patients (26.79%) developed neutropenia. There were eight male and seven female patients and their average age was 53.73 years old, which is slightly older than control patients but the difference did not reach statistical significance (average age 42.66, *P* = 0.0708). The average neutrophil count was 683.83 mm^3^ (standard deviation = 424.64 mm^3^). The average azathioprine dose (mg/kg/day) is higher among the case group while the average body weight is lower than the control group.

In patients with neutropenia, eight were heterozygous for*NUDT15* (C/T), four patients had C/C, and three patients had homozygous variant (T/T) (Table [2](#Tab2){ref-type="table"}). None of the four patients with C/C carried*TPMT* mutation. Grade 2--4 neutropenia occurred in four, seven, and four patients, respectively. The interval between the dates from azathioprine use to the lowest neutrophil count ranged between 14 and 140 days. Ten patients developed neutropenia within 8 weeks and all 15 patients developed it within 6 months. Considering the patients' genotypes, the average interval in the C/C group (70.75 ± 46.84 days) is longer than that in patients with C/T (67.88 ± 35.18 days) and patients with T/T (26.33 ± 19.66 days). However, the difference did not reach statistical significance (*P* = 0.2362). The average neutrophil count did not correlate with the copy numbers of*NUDT15* variant C to T allele. The average neutrophil count was 701.79 mm^3^ (standard deviation = 544.77 mm^3^) in the C/C group, 819.81 mm^3^ (standard deviation = 320.82 mm^3^) in the C/T group, and 297.26 mm^3^ (standard deviation = 397.59 mm^3^) in the T/T group. The difference between groups was not statistically significant. The age-, sex-, and dose-adjusted risk of carrying heterozygous variant compared to wild type is 9.383 (95% CI 1.32--66.96). The odds ratio of early neutropenia did not reach significance (OR 16.529; 95% CI 0.67--405.82) (Table [3](#Tab3){ref-type="table"}).Table 2Clinical and genetic characteristics of the 15 patients had azathioprine-induced leukopenia*NUDT15* C/C*NUDT15* C/T*NUDT15* T/TANOVA testPatient numbers483Age ± SD (years)64.00 ± 23.4552.63 ± 22.3243.00 ± 21.280.4839Sex (male to female)1:34:43:00.2037Underlying disease1.000\* Generalized eczema362 Atopic dermatitis111 Bullous pemphigoid010Neutrophil count701.79 ± 544.77819.81 ± 320.82297.26 ± 397.590.1978Interval70.75 ± 46.8467.88 ± 35.1826.33 ± 19.660.2362Early neutropenia2 (50%)5 (62.5%)3 (100%)0.6084\*\*Fisher's exact testTable 3Age-, sex-, and dose-adjusted odds ratio (OR) of neutropenia*NUDT15* R139CGenotype frequency number (%)OR (95% CI)C/CC/TT/TNeutropenia4 (11.11)8 (47.06)3 (100)9.383 (1.32--66.96)Early neutropenia2 (55.56)5 (29.41)3 (100)16.529 (0.67--405.82)Late neutropenia2 (55.56)3 (17.65)08.269 (0.69--94.31)Controls32 (88.89)9 (52.94)0Early neutropenia defined as neutropenia developed within 8 weeks

Among all the patients, 17 episodes of adverse effect besides neutropenia happened in ten patients during the treatment courses. However, none of the patients discontinued oral administration of azathioprine because of adverse effects other than neutropenia. Adverse effects included nausea, gastrointestinal discomfort, sore throat, oral ulcer, hair loss, fatigue, urticaria, elevated liver function test, anemia, and thrombocytopenia. Two patients with homozygous variant (T/T) developed multiple adverse effects. One patient had grade 4 neutropenia, anemia, thrombocytopenia, nausea, hair loss, and oral ulcers. The other patient had grade 4 neutropenia, anemia, thrombocytopenia, nausea, hair loss, and general malaise. Clinical and genetic characteristics of the patients with azathioprine-induced leukopenia are shown in Table [4](#Tab4){ref-type="table"}.Table 4Clinical and genetic characteristics of the patients with azathioprine-induced leukopeniaCaseDose of AZA (mg/kg/day)Neutropenia develops days after start AZA ≥ 1 mg/kg/dayLowest neutrophil countOther side effects*TPMT* gene c.719A\>G (p.Y240C)*NUDT15* gene c.415C\>T (p.R139C)11.721519WTC/C21.411629Alopecia, malaise, nausea, pancytopeniaWTT/T31.0449109Alopecia, nausea, pancytopenia, oral ulcerWTT/T41.7865149WTC/T51.35109569WTC/C62.00103583WTC/T71.15140735UrticariaWTC/T81.2514754WTT/T91.4749919AnemiaWTC/C102.3448971WTC/T111.8842991WTC/T122.08471001Poor appetiteWTC/T132.00511029WTC/T141.67471100WTC/T152.001101300GI upset, sore throatWTC/C*AZA* azathioprine, *GI* gastrointestinal, *NUDT15* nucleoside diphosphate-linked moiety X motif 15, *TPMT* thiopurine methyltransferase, *WT* wide type

Discussion {#Sec4}
==========

We enrolled 56 consecutive patients with different dermatological diseases treated orally with azathioprine. There was no difference of patients' age, underlying diseases, and genotypes among different gender. However, the average azathioprine dose was slightly higher in female patients. It could be explained by the significantly lower average body weight in female patients. The dose of azathioprine per tablet is 50 mg and it was usually prescribed as whole tablets.

Major adverse events from azathioprine occurred in about 4% of patients, mainly leukopenia and abnormal liver function. Previous studies have implicated the role of*TPMT* and*ITPA* genetic polymorphism in the pathogenesis in Caucasians, but the roles of these two genes were not found in Asian patients for either drug toxicity \[[@CR7]\] or treatment efficacy \[[@CR4], [@CR16]\].

Subsequent studies have explored the roles of*NUDT15* mutation in azathioprine-induced leukopenia among Asian and Hispanic patients \[[@CR9]--[@CR18]\]. But most of the reports included patients with leukemia or inflammatory bowel diseases. Reports in patients with dermatologic diseases are limited and the number of patients is small \[[@CR20]\]. Our study suggested an important role of*NUDT15* in developing neutropenia among Han Chinese patients with dermatological diseases. Patients with heterozygous variant (C/T) have higher odds ratio (odds ratio 9.383) of developing neutropenia compared to those with wild type. All three patients with homozygous variant (T/T) of*NUDT15* developed neutropenia; two of them developed grade 4 neutropenia and one had grade 3 neutropenia. Patients with homozygous variant tend to develop multiple side effects including severe and early neutropenia. Although the patients who developed neutropenia had used a higher average dose of azathioprine per kilogram per day compared to those in the control group, they had lower body weight. The exact dose was similar in both groups without statistical significance. After adjustment for sex, age and the azathioprine dose, the*NUDT15* variants still carry predictive value of developing neutropenia. The finding is consistent with previous studies among Hispanic and other Asians, including Chinese, Koreans, Japanese, and Thai \[[@CR9]\].

More than half of the patients who developed neutropenia (10/15, 66.67%) had developed early neutropenia in our study. All of them had developed neutropenia within half a year. One patient who carries wild-type*NUDT15* developed neutropenia 109 days after concomitant use of azathioprine and febuxostat, a known inhibitor of azathioprine metabolism. After discontinuation of azathioprine, the patient had recovered with supportive care.

According to the suggestion from Clinical Pharmacogenetics Implementation Consortium 2018 \[[@CR21]\], when*NUDT15* intermediate metabolizer was identified or suspected, azathioprine should be initiated orally at reduced starting doses. A 30--80% of standard dose should be given with slow titration according to the disease and the degree of myelosuppression. If the patient carries homozygous variant, 10% of starting dose should be tested first for malignant disease and alternative treatment should be used for non-malignant disease. Our patients usually used relatively low starting doses of azathioprine, and most of them did not use more than 2 mg/kg/day. After the occurrence of neutropenia, oral administration of azathioprine would be discontinued, and alternative treatment would be given. However, one of our patients who carried heterozygous variant had received a rechallenge of azathioprine, and did not develop another episode of neutropenia under regular follow-up. In addition, one patient with wild-type*NUDT15* had developed the earliest onset of neutropenia, which implied that other genetic polymorphism or non-genetic factors might also be important. Frequent laboratory follow-up is highly recommended, especially within the 6-month period after starting azathioprine.

This is the first report to study the predictive value of*NUDT15* variants on neutropenia specifically in Han Chinese patients with dermatological diseases. Some limitations exist in the study. First, since blood tests were performed regularly, severe neutropenia might be prevented because of early drug withdrawal. However, less severe neutropenia can still be detected. Second, the sample size is relatively small. However, T allele frequency of rs116855232 is found in only 11.96% of the general population in Taiwan \[[@CR22]\] as compared to 14/30 (46.7%) in our study. Third, this is a retrospective study with possible bias. However, it might be unethical to do a prospective study giving the known role of*NUDT15* in other diseases.

Conclusions {#Sec5}
===========

The*NUDT15* variants were found to be associated with higher risk of neutropenia. However, about one quarter of the patients with azathioprine-induced neutropenia in our study carried no mutation of*NUDT15*. Thus, a larger study is still needed to confirm our finding. Although pretreatment screening of*NUDT15* might reduce the chance of azathioprine-induced neutropenia, clinical pharmacovigilance is still most important since both early and delayed neutropenia may develop even in patients who carry normal*NUDT15* genes.
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